| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/15/2004 | DE20320103U1 Composition for topical treatment of skin, useful for treating e.g. eczema and pruritus, comprises a fatty alcohol and three specific plant extracts |
| 07/15/2004 | DE202004006157U1 Pharmaceutical or dietetic product useful for treating headache and migraine comprises a blueberry extract together with vitamins and minerals |
| 07/15/2004 | DE10300222A1 Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen The use of active substances for the prophylaxis and / or therapy of viral diseases |
| 07/15/2004 | DE10300049A1 Neue Verbindungen, die Faktor VIIa inhibieren Novel compounds which inhibit factor VIIa |
| 07/15/2004 | DE10300015A1 Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen Iminosäurederivate as inhibitors of matrix metalloproteinases |
| 07/15/2004 | DE10261696A1 Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base The transdermal administration of rotigotine base |
| 07/15/2004 | DE10261061A1 Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit Dietary food for positively influencing cardiovascular health |
| 07/15/2004 | DE10260263A1 Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen Use of Tetrahydrobiopterinderivaten for the treatment and nutritional management of patients with amino acid metabolism disorders |
| 07/15/2004 | CA2551576A1 Tumour-inhibiting annellated azepinone derivatives |
| 07/15/2004 | CA2512199A1 Compositions of benzoquinolizine carboxylic acid antibiotic drug |
| 07/15/2004 | CA2512190A1 Benzoquinolizine-2-carboxylic acid-containing compositions |
| 07/15/2004 | CA2511779A1 Use of istradefylline (kw-6002) for the treatment of behavioral disorders |
| 07/15/2004 | CA2511778A1 Method of treating patients exposed to toxic chemical agents |
| 07/15/2004 | CA2511606A1 Therapeutic formulations for the treatment of beta-amyloid related diseases |
| 07/15/2004 | CA2511601A1 1,5-diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators |
| 07/15/2004 | CA2511600A1 Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (paba) |
| 07/15/2004 | CA2511599A1 Therapeutic formulations for the treatment of beta-amyloid related diseases |
| 07/15/2004 | CA2511522A1 Novel proteins and use thereof |
| 07/15/2004 | CA2511356A1 Fc receptor modulating compounds and compositions |
| 07/15/2004 | CA2511217A1 Ophthalmic formulation for the prevention and treatment of ocular conditions |
| 07/15/2004 | CA2511199A1 Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| 07/15/2004 | CA2511178A1 Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
| 07/15/2004 | CA2511174A1 Oligosaccharides and conjugates thereof for the treatement of pseudomonas bacteria infection |
| 07/15/2004 | CA2510788A1 Biocompatible dialysis fluids containing icodextrins |
| 07/15/2004 | CA2510779A1 Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate |
| 07/15/2004 | CA2510770A1 Dehydroepiandrosterone (dhea) congeners for prevention and/or treatment of ulcers |
| 07/15/2004 | CA2510362A1 Methods for evaluating genetic susceptibility and therapy for chronic inflammatory diseases |
| 07/15/2004 | CA2510298A1 Acyclic pyrazole compounds |
| 07/15/2004 | CA2510296A1 Steroid compositions for intraocular use |
| 07/15/2004 | CA2510295A1 Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents |
| 07/15/2004 | CA2510292A1 Methods of treating non-painful bladder disorders using .alpha.2.delta. subunit calcium channel modulators |
| 07/15/2004 | CA2510289A1 Pharmaceutical compositions and method of treating parkinson's disease |
| 07/15/2004 | CA2509835A1 Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof |
| 07/15/2004 | CA2509565A1 Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
| 07/15/2004 | CA2509510A1 Method of using a cox-2 inhibitor and a topoisomerase ii inhibitor as a combination therapy in the treatment of neoplasia |
| 07/15/2004 | CA2509501A1 Compositions and methods for treating upper respiratory congestion |
| 07/15/2004 | CA2509224A1 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 07/15/2004 | CA2508995A1 Use of cytidine-, creatine-, and adenosine-containing compounds and adenosine-elevating compounds for normalizing sleep/wake cycle, treating a sleep disorder or improving cognitive function |
| 07/15/2004 | CA2508985A1 Branched immunomodulatory compounds and methods of using the same |
| 07/15/2004 | CA2508921A1 Quinazoline compounds |
| 07/15/2004 | CA2508913A1 Angiogenic compounds and uses thereof |
| 07/15/2004 | CA2508243A1 Method for treating patients for radiation exposure |
| 07/15/2004 | CA2508222A1 Use of thiazolobenzoheterocycles for treating multiple sclerosis |
| 07/15/2004 | CA2507958A1 Pyrazole compounds as integrin receptor antagonists derivatives |
| 07/15/2004 | CA2507699A1 Heteroarylalkanoic acids as integrin receptor antagonists |
| 07/15/2004 | CA2507511A1 Ester combination local anesthetic |
| 07/15/2004 | CA2489590A1 Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| 07/15/2004 | CA2485429A1 Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase |
| 07/15/2004 | CA2485375A1 Spirocyclic piperidines as mch1 antagonists and uses thereof |
| 07/14/2004 | EP1437408A1 Novel antisense oligonucleotide derivatives against hepatitis c virus |
| 07/14/2004 | EP1437364A2 Polypeptide binding to the androgen receptor and its potential use for treating breast cancer |
| 07/14/2004 | EP1437360A2 C11 Carbamates of macrolide antibacterials |
| 07/14/2004 | EP1437359A2 Novel 3,6-Hemiketals from the Class of 9a-Azalides |
| 07/14/2004 | EP1437358A1 Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient |
| 07/14/2004 | EP1437354A1 4-oxoquinolizine antimicrobials having 2-pyridone skeleton as partial structure |
| 07/14/2004 | EP1437351A1 Amine derivative |
| 07/14/2004 | EP1437349A1 Substituted isoxazoles and the use thereof as antibiotics |
| 07/14/2004 | EP1437344A1 Benzene derivatives,process for preparing the same and use thereof |
| 07/14/2004 | EP1437339A1 Substituted benzoic acid derivatives exhibiting nf-kappa b inhibiting activity |
| 07/14/2004 | EP1437145A1 Enhanced scintigraphic imaging agents for imaging of infection and inflammation |
| 07/14/2004 | EP1437142A1 Cell growth inhibitors |
| 07/14/2004 | EP1437139A2 Method for protection against genotoxic mutagenesis |
| 07/14/2004 | EP1437138A1 Use of 7-oxo DHEA in the modulation of the metabolism of a dieting mammal |
| 07/14/2004 | EP1437137A1 Drugs comprising combination of antithrombotic agent with pyrazolone derivative |
| 07/14/2004 | EP1437136A1 Compositions comprising cannabinoids |
| 07/14/2004 | EP1437134A1 Anti-influenza drugs |
| 07/14/2004 | EP1437133A1 Amines with antialcoholic agents |
| 07/14/2004 | EP1437132A1 Use of nitric ester derivatives in the manufacture of a medicament for the treatment of gastrointestinal tumors |
| 07/14/2004 | EP1437131A1 Use of an ACE inhibitor for the prevention of diabetes in a patient with no preexisting congestive heart failure |
| 07/14/2004 | EP1437130A1 Percutaneous absorption preparations |
| 07/14/2004 | EP1437127A1 Suspension comprising oxcarbazepine |
| 07/14/2004 | EP1437126A1 Compositions used to alleviate xerostomia and to treat disorders associated with same |
| 07/14/2004 | EP1437121A1 Anti-dandruff composition for hair and scalp |
| 07/14/2004 | EP1437052A1 Ocuvite Zinc |
| 07/14/2004 | EP1436877A2 An intelligent serial battery charger and charging block |
| 07/14/2004 | EP1436623A1 Modulation of tor |
| 07/14/2004 | EP1436607A1 Ion-sensitive field effect transistor and a method for producing a transistor of this type |
| 07/14/2004 | EP1436429A2 Targeted nucleic acid constructs and uses related thereto |
| 07/14/2004 | EP1436418A2 Transductin-1 and transductin-2 and applications to hereditary deafness |
| 07/14/2004 | EP1436403A2 Use of the adenoviral e2 late promoter |
| 07/14/2004 | EP1436395A2 Methods for identifying and using modulators of estrogen related receptor gamma |
| 07/14/2004 | EP1436389A2 Thrombin-cleavable chimeric proteins |
| 07/14/2004 | EP1436380A2 Composition comprising a lactobacillus pentosus strain and uses thereof |
| 07/14/2004 | EP1436345A1 Quaternary polyamidoamines, the production thereof, corresponding agents and the use thereof |
| 07/14/2004 | EP1436330A2 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 07/14/2004 | EP1436327A1 Ee3-protein family and corresponding dna sequences |
| 07/14/2004 | EP1436316A2 Subcellular targeting of therapeutic proteins |
| 07/14/2004 | EP1436311A2 Antisense oligonucleotides and methods to induce tumor cell death |
| 07/14/2004 | EP1436303A1 Pharmaceutically acceptable alendronate salts in amorphous form |
| 07/14/2004 | EP1436298A1 Himbacine analogues as thrombin receptor antagonists |
| 07/14/2004 | EP1436295A2 Crystalline forms of valacyclovir hydrochloride |
| 07/14/2004 | EP1436294A1 Tetracyclic azaindoles and -indolines having serotonin 5-ht2c activity |
| 07/14/2004 | EP1436293A1 Polycyclic compounds having anti-tumor activity |
| 07/14/2004 | EP1436292A1 5-methoxy-8-aryl-[1,2,4]triazolo[1,5-a]pyridine derivatives as adenosine receptor antagonists |
| 07/14/2004 | EP1436291A2 Indolizines as kinase protein inhibitors |
| 07/14/2004 | EP1436290A1 Alkyne-aryl-naphthyridin-4(1h)-0ne derivatives as type iv phosphodiesterase inhibitor |
| 07/14/2004 | EP1436287A2 Small organic molecule regulators of cell proliferation |
| 07/14/2004 | EP1436285A2 Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles |
| 07/14/2004 | EP1436283A1 Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof |
| 07/14/2004 | EP1436281A1 Piperidine- and piperazineacetamides as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |